Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03914495 · ClinicalTrials.gov registry record · NA
The Role of Microbiome Reprogramming on Liver Fat Accumulation
A NA study, sponsored by AdventHealth Translational Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT03914495 is a NA study that was terminated before completion, run by AdventHealth Translational Research Institute. The registered enrollment target is 57 participants.
The verdict
NCT03914495, a NA study, was terminated before completion, sponsored by AdventHealth Translational Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Inulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2021-06-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03914495
The ClinicalTrials.gov registry entry for NCT03914495 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03914495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03914495 about?
NCT03914495 is a clinical study titled "The Role of Microbiome Reprogramming on Liver Fat Accumulation". The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
What is the current status of trial NCT03914495?
This trial is currently terminated. It is a NA study. The enrollment target is 57 participants. The study started on 2019-05-21. Estimated completion is 2021-06-09.
What interventions are being tested in trial NCT03914495?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Inulin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03914495?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.